Parabilis Medicines, Inc. PBLS
27.63 USD -0.84 (-2.97%)
Regular-session close
27.63 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
27.17 Day range 28.92
22.66 52-week range 42.49
- YTD
- -12.58%
- 1 year
- -12.58%
News
zacks.com Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect? The mean of analysts' price targets for Parabilis Medicines (PBLS) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…benzinga.com Parabilis Medicines Q3 EPS $(0.36), Inline, Sales $2.114M Beat $375.000K Estimate Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 98.34 percent increase over losses of $(21.66) per share from the…
globenewswire.com Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in…benzinga.com Canaccord Genuity Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $39 Canaccord Genuity analyst John Newman initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $39.
benzinga.com HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40 HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.
benzinga.com Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.benzinga.com Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026 Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid…
